Advocating AI - driven Digital Pathology

aetherAI’s mission is to use state-of-the-art information technology to improve standards of healthcare and quality of human life.

Milestones

Received ISO/IEC 27001 certification, demonstrating a commitment to information security management.

Awarded the inaugural "adi15 Digital Innovation Award" by the Ministry of Digital Affairs.

Honored in the "2023 Taiwan AI Award" jointly selected by "Business Next" and the Ministry of Digital Affairs.

Achieved dual victories in Arm 1 and Arm 2 of the #SemiCOL challenge at ECDP2023 in Budapest, Hungary, hosted by the European Society of Digital and Integrative Pathology, proving our excellence in AI technology.

2023

aetherAI Hema successfully passed the review under the Act for the Development of Biotech and Pharmaceutical Industry, included in the recommended list of domestic medical devices for hospital procurement, becoming a key indicator in hospital evaluations.

Collaborated with Changhua Christian Hospital to apply the Digital Pathology System aetherSlide across the widest medical center coverage in Taiwan, including Changhua, Yunlin, Taichung, and Nantou, facilitating pathological diagnosis and enhancing cancer review quality.

Partnered with Cathay General Hospital and Cathay Healthcare Inc. to fully implement the aetherAI Endo Computer-aided Polyp Detection (CADe) Systems for Colonoscopy, increasing polyp detection rates, reducing colorectal cancer risks, and improve the health of people.

Collaborated with the CGMH Group have been collaborating on digital pathology transformation since 2019, saving doctors cross-hospital communication time through digital review, and will start deploying AI artificial intelligence in 2023. After integrating with the information system, clinical cases will be introduced to assist diagnosis.

Has completed A+ round funding of 150 million NTD from Ono Digital Health Investment LLC, Quanta Computer, TBB Venture Capital, and Taimage Investment.

aetherAI Hema won 3 awards: Taipei Biotech Award Gold Medal, PTRD Gold, and Taiwan Excellence Award.

2022

aetherAI Endo, Computer-aided Polyp Detection (CADe) Systems for Colonoscopy has been approved by TFDA in July 2022.

Expanding the global market. Major achievements: collaborated projects in Japan, and deployment for the University Hospital Tübingen in digital pathology and AI applications.

Has become one of the partners of EMPAIA, Eco-system for Pathology Diagnostic with AI Assistance.

Teamed up with Cathay Financial Holdings in medical underwriting AI and won 2022 FinTech Taipei Award.

aetherAI Joe Yeh won the 2022 Best Bio Startup CEO Award.

aetherAI Apps aetherAI-IHCQ-BC and aetherAI-LNMD-GA obtained EU CE-IVDD medical device certification.

2021

Taiwan government rolls out Asia Silicon Valley Department Plan 2.0 (2021–2024) to expand AIoT applications, which is expected to encourage a digital transformation in healthcare.

Introduced Computer-aided Polyp Detection (CADe) Systems for Colonoscopy aetherAI Endo.

aetherAI’s annotation-free whole-slide training approach published with global recognition in leading journal Nature Communications.

Partnership with Novartis Taiwan and Linkou CGMH to use AI to improve diagnosis of blood disease.

Revenues triple for third year in a row, expanding into global markets.

TAIPEI Prominent Enterprise Award—R&D Award, Judge’s Award.

2020

mplementations of digital pathology for National Taiwan University Hospital, Taiwan’s top medical centers, and CGMH Group, Taiwan’s largest private hospital group. The latter is the largest digital pathology project in Taiwan.

Series A from Quanta Computer.

Introduction of aetherAI Hema, world’s first automated AI system for bone marrow differentials.

The government’s Six Core Strategic Industries Program is created to transform Taiwan’s biotech and medical technology. The inclusion of information and digital technology is expected to boost smart healthcare development.

2019

Business Startup Award by Ministry of Economic Affairs, Taiwan, ROC.

Seed funding round with investment from Cathay Venture.

Optimized pipelines for training DNNs on whole-slide images.

2018

Training multiple AI models with top medical centers in the US and Taiwan, including UPMC, National Taiwan University Hospital, Taipei Veterans General Hospital, and CGHM.

Meet Neo Star Demo Show Award Winner.

NVIDIA GTC Inception Award Winner.

2017

Beginning of collaboration with CGMH, Chang Gung Memorial Hospital, Taiwan’s largest private hospital group.

Introduction of AI medical imaging development platform.

2016

1st project: computer-aided detection of circulating tumor cells on whole slide images.

OCT

2015

Founding of aetherAI.

Introduced Computer-Aided Lung Nodule Detection System with Low-Dose CT.

aetherAI Hema, Bone Marrow Smear Analysis Software is the first AI-assisted bone marrow smear differential count medical device in the world, which had received TFDA approval and CE-marked.

Meet the Team

Joe Yeh

M.D., Co-founder & CEO.

Dr. Joe Yeh holds an M.D. from National Taiwan University and studied for a doctorate in pathology at the University of Southern California, where he discovered his passion for computer programming and image analysis. Inspired by the power of computer algorithms to perform rapid, accurate image analysis and the potential to improve healthcare, Dr. Yeh left academia and founded aetherAI with KJB and Steven Yeh.

Dr. Yeh has taught deep learning in medical imaging at National Taiwan University's Department of Biomedical Engineering and National Cheng Kung University’s Department of Electrical Engineering. He has co-authored several research papers published in prestigious international publications such as Nature Communications.

Steve Yeh

Co-founder and COO

KJB, M.S.

Co-founder and CTO

Sean Yu, M.S.

VP of Data Science

Core Business

Asia’s leading medical image AI solution provider, aetherAI is dedicated to providing cutting-edge solutions for digital pathology transformation, AI-powered diagnostic support systems, and biopharma enterprise services.

By leveraging state-of-the-art technologies, aetherAI aims to ease the burden on healthcare professionals and improve diagnostic imaging quality. At the forefront of digital pathology AI, aetherAI partners with top medical centers in the US, Taiwan, Japan, and Europe, including UPMC, National Taiwan University Hospital, Kanazawa University, University Hospital Tübingen, etc. aetherAI is also a trusted collaborator for such BioPharma companies as Novartis Taiwan and ACT Genomics, and many more are working with us to accelerate AI applications for research efficiency.